ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)

ImPact Biotech announced that the first patient has been treated in its Phase I trial evaluating Padeliporfin vascular targeted photodynamic (VTP) in individuals with locally advanced, unresectable PDAC at the UCI Irvine Medical Center.